We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
(+21%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
32.16%
Top 10 Holdings %
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Realty Income
O
|
+$931K |
| 2 |
SK Telecom
SKM
|
+$871K |
| 3 |
Moderna
MRNA
|
+$825K |
| 4 |
ConocoPhillips
COP
|
+$786K |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$785K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agnico Eagle Mines
AEM
|
+$1.83M |
| 2 |
BPMP
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
|
+$1.76M |
| 3 |
The Mosaic Company
MOS
|
+$928K |
| 4 |
STR
Sitio Royalties
STR
|
+$559K |
| 5 |
Gold Fields
GFI
|
+$512K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.55% |
| 2 | Healthcare | 17.07% |
| 3 | Materials | 11.98% |
| 4 | Financials | 11.43% |
| 5 | Energy | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Denali Therapeutics
DNLI
$3.81B
| $142K | 0.05% |
4,839
+1,406
| +41% | +$36.8K |
|
327
Xencor
XNCR
$1.48B
| $142K | 0.05% |
5,185
+593
| +13% | +$14.6K |
|
328
Kymera Therapeutics
KYMR
$9.22B
| $141K | 0.05% |
7,171
+4,273
| +147% | +$99.8K |
|
329
Phathom Pharmaceuticals
PHAT
$959M
| $141K | 0.05% |
16,726
+8,151
| +95% | +$83.8K |
|
330
Kura Oncology
KURA
$927M
| $139K | 0.05% |
7,592
-5,009
| -40% | -$72.1K |
|
331
Intellia Therapeutics
NTLA
$1.52B
| $139K | 0.05% |
2,694
+1,341
| +99% | +$68.1K |
|
332
Edgewise Therapeutics
EWTX
$4.49B
| $138K | 0.05% |
17,341
+9,212
| +113% | +$69.6K |
|
333
Fate Therapeutics
FATE
$287M
| $138K | 0.05% |
5,566
+2,475
| +80% | +$68.3K |
|
334
Novavax
NVAX
$1.25B
| $138K | 0.05% |
2,679
+1,758
| +191% | +$91.1K |
|
|
INBX
335
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $138K | 0.05% |
12,172
+8,204
| +207% | +$121K |
|
336
Nurix Therapeutics
NRIX
$2.48B
| $136K | 0.05% |
10,735
+5,059
| +89% | +$57.3K |
|
337
Recursion Pharmaceuticals
RXRX
$1.61B
| $136K | 0.05% |
16,726
+8,405
| +101% | +$56.2K |
|
338
Krystal Biotech
KRYS
$10.5B
| $135K | 0.05% |
2,055
-144
| -7% | -$8.96K |
|
339
Rocket Pharmaceuticals
RCKT
$361M
| $135K | 0.05% |
9,792
+3,000
| +44% | +$35.8K |
|
340
Adicet Bio
ACET
$77.2M
| $134K | 0.05% |
574
-105
| -15% | -$23.1K |
|
341
Zentalis Pharmaceuticals
ZNTL
$328M
| $134K | 0.05% |
4,786
+2,617
| +121% | +$69.3K |
|
|
BCYC
342
Bicycle Therapeutics
BCYC
$279M
| $133K | 0.05% |
7,946
+4,959
| +166% | +$105K |
|
|
KRTX
343
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $133K | 0.05% |
1,048
-319
| -23% | -$36.7K |
|
|
MRTX
344
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $133K | 0.05% |
1,975
+861
| +77% | +$54.8K |
|
345
Seres Therapeutics
MCRB
$47.6M
| $132K | 0.05% |
1,920
+958
| +100% | +$82.5K |
|
346
Alector
ALEC
$168M
| $131K | 0.05% |
12,898
+5,542
| +75% | +$55.3K |
|
347
Arrowhead Research
ARWR
$12.2B
| $131K | 0.05% |
3,718
+1,460
| +65% | +$54.9K |
|
|
IGMS
348
DELISTED
IGM Biosciences
IGMS
| $131K | 0.05% |
7,267
+1,798
| +33% | +$32K |
|
349
Stoke Therapeutics
STOK
$1.85B
| $131K | 0.05% |
9,895
+1,336
| +16% | +$20.3K |
|
350
Allogene Therapeutics
ALLO
$614M
| $130K | 0.05% |
11,383
+535
| +5% | +$4.75K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.
Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.
By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.
- Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
- Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
- Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
- Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
- Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
- Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
- Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.
Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.